Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical company specializing in neurodegenerative disease treatments, has announced a significant milestone in its intellectual property strategy. The company has successfully secured full patent coverage for both the original and a new crystalline form of buntanetap, its lead compound. This comprehensive patent protection, extending through 2046, encompasses the composition of matter, mechanism of action, and use across multiple indications, solidifying Annovis Bio's position in the neurodegenerative disease therapeutic space.
The new crystalline form of buntanetap has demonstrated improved stability, with bioequivalence confirmed in both animal and human studies. These findings were recently presented at the 2025 Alzheimer’s Association International Conference, highlighting the potential of buntanetap to offer more reliable and effective treatment options for patients suffering from Alzheimer’s disease (AD) and Parkinson’s disease (PD). The expansion of the patent portfolio is a critical step in ensuring that Annovis Bio can continue to develop and commercialize buntanetap without the threat of competition from generic alternatives, thereby securing the company's investment in this promising therapeutic avenue.
Neurodegenerative diseases, such as AD and PD, represent a growing challenge to global health systems, with millions of patients worldwide in need of effective treatments. The development of buntanetap, with its novel mechanism of action targeting the underlying pathology of these diseases, offers hope for slowing or even halting disease progression. The securing of full patent coverage for buntanetap not only protects Annovis Bio's intellectual property but also ensures that the company can attract the necessary investment to advance clinical trials and, ultimately, bring this potentially transformative treatment to market.
For more information on Annovis Bio Inc. and its groundbreaking work in neurodegenerative disease treatment, visit https://www.annovisbio.com. Additional details on the patent coverage and the implications for the future of neurodegenerative disease treatment can be found in the full press release at https://ibn.fm/gtiNb.
